Auvelity is a prescription antidepressant approved by the FDA in 2022 for the treatment of major depressive disorder (MDD) in adults. It combines two active ingredients, dextromethorphan and bupropion, in a single tablet and works through a different mechanism than traditional antidepressants like SSRIs. One of its most notable features is speed: clinical trials showed rapid symptom improvement in as early as one week, compared to the four to six weeks most antidepressants typically require.
How Auvelity Works
Most antidepressants target serotonin, norepinephrine, or dopamine. Auvelity takes a different approach. Its primary active ingredient, dextromethorphan, affects a receptor system in the brain called the NMDA pathway, which is involved in how brain cells communicate and adapt. By modulating this system, dextromethorphan can influence mood through pathways that older antidepressants don’t touch.
So why is bupropion in there? Bupropion serves a dual purpose. It has its own antidepressant effects, working on dopamine and norepinephrine. But its main role in this combination is more practical: your body normally breaks down dextromethorphan very quickly, which would make it ineffective as a mood treatment. Bupropion blocks the liver enzyme responsible for that rapid breakdown, allowing dextromethorphan to stay in the bloodstream long enough to work. Without bupropion, dextromethorphan would be metabolized too fast to have a meaningful antidepressant effect.
How Quickly It Works
The speed of Auvelity’s effect is what sets it apart from most other oral antidepressants. In the GEMINI trial, a six-week placebo-controlled study, patients experienced statistically significant improvements in depressive symptoms within the first week of treatment. Traditional SSRIs and SNRIs generally take four to six weeks before patients notice meaningful relief, though some improvement can begin in the first two weeks.
This faster onset matters in practical terms. Depression affects daily functioning, relationships, and work. Shaving weeks off the time it takes to feel better can make a real difference, especially for people who have cycled through multiple medications waiting for each one to kick in.
How It’s Taken
Each Auvelity tablet contains 45 mg of dextromethorphan and 105 mg of bupropion. The starting dose is one tablet once daily in the morning. After three days, the dose increases to one tablet twice daily, taken at least eight hours apart. You can take it with or without food. Two tablets per day is the maximum dose.
Common Side Effects
In the GEMINI clinical trial, the most frequently reported side effects were:
- Dizziness (16% of participants)
- Headache (8%)
- Diarrhea (7%)
- Drowsiness (7%)
- Dry mouth (6%)
- Sexual dysfunction (6%)
- Excessive sweating (5%)
Dizziness was the standout side effect, affecting roughly one in six people. This is more common than with most SSRIs, though it often improves after the first few days. The sexual dysfunction rate of 6% is notably lower than what’s typically seen with SSRIs, where rates of 30% to 70% have been reported in some studies. For people who’ve stopped previous antidepressants because of sexual side effects, this can be a meaningful advantage.
Who Should Not Take Auvelity
Auvelity is not appropriate for everyone. Because it contains bupropion, which can lower the seizure threshold, it is contraindicated in people with seizure disorders. It’s also contraindicated if you have a current or prior diagnosis of anorexia nervosa or bulimia, as these conditions already increase seizure risk.
If you’re going through withdrawal from alcohol, benzodiazepines, barbiturates, or anti-seizure medications, Auvelity should not be started. The abrupt discontinuation of those substances already raises seizure risk, and adding bupropion compounds the danger.
People with severe kidney or liver impairment should avoid Auvelity, since both organs play a role in processing the drug’s components. Certain medications that strongly affect how the liver processes bupropion should also not be combined with it. Like all antidepressants, Auvelity carries a boxed warning about increased risk of suicidal thoughts and behavior in children, adolescents, and young adults, though the drug is approved only for adults.
Where Auvelity Fits Among Antidepressants
Auvelity occupies a unique space. It’s the first oral antidepressant with an NMDA-targeting mechanism to receive FDA approval, making it a genuinely new class of treatment rather than another variation on existing drugs. Before Auvelity, the only NMDA-related depression treatments were ketamine (given intravenously in clinics) and its nasal spray derivative, both of which require in-office administration and monitoring.
For people starting depression treatment for the first time, SSRIs remain the most common first-line option. Auvelity is particularly relevant for people who haven’t responded well to traditional antidepressants, who need faster relief, or who’ve been unable to tolerate the sexual side effects common with serotonin-based medications. Its oral format and at-home dosing make it far more accessible than ketamine-based alternatives.